WO2012058666A3 - Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy - Google Patents

Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy Download PDF

Info

Publication number
WO2012058666A3
WO2012058666A3 PCT/US2011/058558 US2011058558W WO2012058666A3 WO 2012058666 A3 WO2012058666 A3 WO 2012058666A3 US 2011058558 W US2011058558 W US 2011058558W WO 2012058666 A3 WO2012058666 A3 WO 2012058666A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
compound
water
cancer therapy
Prior art date
Application number
PCT/US2011/058558
Other languages
French (fr)
Other versions
WO2012058666A2 (en
Inventor
Fengzhi Li
Xiang Ling
Shousong Cao
Original Assignee
Health Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US40799610P priority Critical
Priority to US61/407,996 priority
Application filed by Health Research, Inc. filed Critical Health Research, Inc.
Publication of WO2012058666A2 publication Critical patent/WO2012058666A2/en
Publication of WO2012058666A3 publication Critical patent/WO2012058666A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Abstract

Provided are compositions, methods of making the compositions, and methods of using the compositions. The compositions can be provided as pharmaceutical preparations for use in disease treatment, such as cancer therapy. The compositions include novel pharmaceutical preparations which contain effective concentrations of a chemical compound. One compound used is 10H-1,3-Dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2-b] quinoline-8,11(7H,12H)-dione, 7-ethyl-7- hydroxy-, (S)-. The invention also provides methodologies for preparing pharmaceutical preparations for use in intravenous and oral pharmaceutical preparations that contain drug compounds that are difficult to dissolve in water.
PCT/US2011/058558 2010-10-29 2011-10-31 Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy WO2012058666A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US40799610P true 2010-10-29 2010-10-29
US61/407,996 2010-10-29

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11837250.7A EP2632264B1 (en) 2010-10-29 2011-10-31 Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy
CA2816418A CA2816418C (en) 2010-10-29 2011-10-31 Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy
CN201180063530.5A CN103442565B (en) 2010-10-29 2011-10-31 Use non-water soluble compounds new formulation and the method for the compound FL118 preparation for treatment of cancer
US13/881,785 US9422303B2 (en) 2010-10-29 2011-10-31 Formulations of water-insoluble chemical compounds and methods of using a formulation of compound FL118 for cancer therapy

Publications (2)

Publication Number Publication Date
WO2012058666A2 WO2012058666A2 (en) 2012-05-03
WO2012058666A3 true WO2012058666A3 (en) 2013-01-10

Family

ID=45994848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/058558 WO2012058666A2 (en) 2010-10-29 2011-10-31 Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy

Country Status (5)

Country Link
US (1) US9422303B2 (en)
EP (1) EP2632264B1 (en)
CN (1) CN103442565B (en)
CA (1) CA2816418C (en)
WO (1) WO2012058666A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106715443A (en) * 2014-03-26 2017-05-24 坎格特生物技术制药有限责任公司 Use of the FL118 core chemical structure platform to generate FL118 derivatives for treatment of human disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0556585A2 (en) * 1992-01-24 1993-08-25 Takeda Chemical Industries, Ltd. Condensed camptothecin derivatives their production and use as antitumor agents
US6653319B1 (en) * 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
WO2001074401A2 (en) * 2000-03-31 2001-10-11 Supergen, Inc. Camptothecin complexes
AU2001270385B2 (en) 2000-06-30 2006-05-25 Talon Therapeutics, Inc. Liposomal antineoplastic drugs and uses thereof
US6509027B2 (en) * 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
WO2008073201A2 (en) 2006-11-10 2008-06-19 Health Research Inc. Compositions and methods for identifying agents that alter expression of survivin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0556585A2 (en) * 1992-01-24 1993-08-25 Takeda Chemical Industries, Ltd. Condensed camptothecin derivatives their production and use as antitumor agents
US6653319B1 (en) * 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM [online] 27 March 2005 (2005-03-27), XP003031894, retrieved from NCBI Database accession no. CID 437971 *
See also references of EP2632264A4 *

Also Published As

Publication number Publication date
CA2816418C (en) 2020-05-26
EP2632264A4 (en) 2014-04-23
CN103442565A (en) 2013-12-11
EP2632264A2 (en) 2013-09-04
CN103442565B (en) 2016-08-10
US9422303B2 (en) 2016-08-23
EP2632264B1 (en) 2019-10-02
WO2012058666A2 (en) 2012-05-03
CA2816418A1 (en) 2012-05-03
US20140066470A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
CN105294683B (en) Compound of CDK type small molecular inhibitors and application thereof
CN105294682B (en) Compound of CDK type small molecular inhibitors and application thereof
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
BR112015019508A8 (en) solid forms of a selective cdk4 / 6 inhibitor
IL244239D0 (en) (2s,5r)-6-(benzyloxy/allyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylates, process for their preparation and use of (2s,5r)-tert-butyl-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboyxlate for preparing anti-infective medicaments
TW201613593A (en) Molecules for administration to ROS1 mutant cancer cells
WO2013173129A3 (en) Treatment of amd using aav sflt-1
EA201590870A1 (en) AMINO-SUBSTITUTED IMIDAZO [1,2-a] Pyridinecarboxamides and their use
IL229229D0 (en) Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
CY1121485T1 (en) Imiquimod formulations and dosages lower power rock dosage regimen deal actinic keratosis
PH12016500040A1 (en) Pcsk9 vaccine
NZ627900A (en) Macrocyclic derivatives for the treatment of proliferative diseases
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
HRP20120968T1 (en) Compounds
IL217378A (en) Oxazine derivatives, pharmaceutical compositions comprising them and their use for the preparation of medicaments for the treatment of neurological disorders
IL229193D0 (en) Pyridin-2(1h)-one derivatives useful useful as medicaments for the treatment of myeloproliferative disorders,transplant rejection,immune-mediated and inflammatory diseases
EA201490647A1 (en) Derivatives of benzothiazol-6-lucus acid and their application for the treatment of hiv infection
SI2844637T1 (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
MX353654B (en) Anticancer pyridopyrazines via the inhibition of fgfr kinases.
MX2013002337A (en) Small liposomes for delivery of immunogen-encoding rna.
IL215665D0 (en) Nanoparticle formulations and uses therof
MD4490C1 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
MX2013007148A (en) 2-arylimidazo[1,2-b]pyridazine, 2-phenylimidazo[1,2-a]pyridine, and 2-phenylimidazo[1,2-a]pyrazine derivatives.
MX349004B (en) New compounds.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11837250

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2816418

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011837250

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13881785

Country of ref document: US